ACAD - Acadia Pharmaceuticals Inc - Page 4

ACAD Share Statistics


Average Volume (3 month)3:855,749
Average Volume (10 day)3:1,106,790

Shares Outstanding5:38.27M
Float:32.81M

% Held by Insiders1:19.63%
% Held by Institutions1:37.10%
Shares Short (as of 30-Nov-09)3:480.19K
Short Ratio (as of 30-Nov-09)3:1.2
Short % of Float (as of 30-Nov-09)3:1.70%
Shares Short (prior month)3:554.64K

Check out shares outstanding and the float, if news is good, this stock is GONE!

I'm in ACAD for 5000 shares right now.

I bought it back in July/August as a covered call. I think my price was around $2.25 or $2.30 even though the stock was trading at around $6.00.

So i'd be happy if it goes up to $2.50 a share.

Pardon my ignorance but where are these yahoo forums?

With that float, if it gets approval, this is primed to explode. I just don't see them getting approved with the data in Phase III. Good luck tho.

My guess is the FDA will want a confirmatory trial.

i dont think you trust or even follow anything from yahoo message board! can anyone support me with thiss!!

100% correct. Probably worse than iHub.

It's climbing in AH.

When I posted earlier it was at $1.41.

I thought after hours trading ended at 1900 eastern time?

Still 20 min left @1.45

Small trades though. When I looked before it was at $1.41 and around 13k volume. Now it's up 4 cents from there with only another 1k volume, give or take.

Yes... One for 4200.

I'm thinking I should have held and played the hype- about 6% ^ in AH.

From what im reading the current raise in price in this stock is coming almost entirely from people reading these sorts of message boards. The volume isn't really large enough at this point to make me think anyone knows anything. They're just hopeful.

So I wouldn't be risking any real money in this bad boy.

I think you are right that ACAD is being noticed on message boards, but I bet this stock has been on a lot of peoples watch list too.

In my opinion ACAD is better than DDSS and DDSS is trading at $2 now, with the low float ACAD has, I think this stock is going to hit $2 also very soon, people are willing to take a chance on this stock, their Parkinson trial has been going on for two years, plus if it is working at all, I think they will want it toe go into phase IV trials.
I like this stocks chances a lot better than HEB or DDSS.

Good luck everyone!

Not doing SHEEEEET! But that is okay, I'm in for the news, I am happy to wait until it comes.

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study is currently recruiting participants.
Verified by ACADIA Pharmaceuticals Inc., February 2009
First Received: October 26, 2007 Last Updated: June 16, 2009 History of Changes
Sponsor:ACADIA Pharmaceuticals Inc.
Information provided by:ACADIA Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:NCT00550238
Purpose
To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.


ConditionInterventionPhase
Parkinson's Disease Psychosis
Drug: pimavanserin tartrate (ACP-103)
Phase III

Study Type:Interventional
Study Design:Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Official Title:A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Resource links provided by NLM:

Genetics Home Reference related topics: familial paroxysmal nonkinesigenic dyskinesia Parkinson disease
MedlinePlus related topics: Parkinson's Disease Psychotic Disorders
Drug Information available for: Pimavanserin tartrate ACP 103
U.S. FDA Resources

Further study details as provided by ACADIA Pharmaceuticals Inc.:

Primary Outcome Measures:
Safety [ Time Frame: Duration of the treatment period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
Safety [ Time Frame: Duration of the treatment period ] [ Designated as safety issue: No ]

Estimated Enrollment:500
Study Start Date:July 2007
Estimated Primary Completion Date:December 2009 (Final data collection date for primary outcome measure)
Intervention Details:
Drug: pimavanserin tartrate (ACP-103)
tablets once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
Eligibility

Ages Eligible for Study: 40 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria:

Subject has completed the treatment period of Study ACP-103-012
The subject is willing and able to provide consent
Caregiver is willing and able to accompany the subject to all visits
Exclusion Criteria:

Subject has current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder
Subject is judged by the Investigator to be inappropriate for the study
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00550238

Contacts
Contact: Kimberly WilsonACP-103clintrials@acadia-pharm.com

Show 43 Study Locations
Sponsors and Collaborators
ACADIA Pharmaceuticals Inc.
More Information

No publications provided

Responsible Party:ACADIA Pharmaceuticals Inc. ( Kimberly Wilson )
Study ID Numbers:ACP-103-015
Study First Received:October 26, 2007
Last Updated:June 16, 2009
ClinicalTrials.gov Identifier:NCT00550238 History of Changes
Health Authority:United States: Food and Drug Administration

Keywords provided by ACADIA Pharmaceuticals Inc.:
Parkinson's Disease Psychosis

Additional relevant MeSH terms:
Mental Disorders
Movement Disorders
Parkinson Disease
Nervous System Diseases
Basal Ganglia Diseases
Central Nervous System Diseases
Psychotic Disorders
Parkinsonian Disorders
Neurodegenerative Diseases
Brain Diseases
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on December 21, 2009

Back to top of Main Content

Contact Help Desk
Lister Hill National Center for Biomedical Communications, U.S. National Library of Medicine,
U.S. National Institutes of Health, U.S. Department of Health & Human Services,
USA.gov, Copyright, Privacy, Accessibility, Freedom of Information Act

Starting to move!

This stock has WAY MORE potential than DDSS, this stock should be way higher than this and will be IMO.

I think a lot of people on HSM will be kicking themselves later for not buying ACAD.

There really isn't much point in buying it right now, unless you like to gamble.

But if you like to gamble, why not take your money to vegas instead? At least there you can gape at hot chicks.

True! But once my money is spent there I'm done.
But how many times have you seen stocks drop to $1 or even .25 cents this year and now see them at $5 to $7.

All stocks are gambling, I just think this one just is more of a fair bet, thats all.

Check out the level II on ACAD, if good news comes with the Phase III trial, we are off to the races.

http://www.level2stockquotes.com/level-ii-quotes.html

10 RATIONAL REASONS TO BE BULLISH ABOUT ACAD


MAIN REASON: RESULTS OF THE SECOND PHASE 3 ARE DUE THIS WEEK AND THEY COULD SURPRISE POSITIVELY BECAUSE MAJORITY OF PATIENTS ARE 2 YEARS ON THE TRAIL WITHOUT QUITTING.

Other reasons:

1) Acadia stock continues to trade 20% below cash value despite the recent positive collaboration with Biovail and acadia’s other four compounds.

2) Besides Biovail, Acadia has relationship with the Michael J. Fox Foundation and Meiji Seika Kaisha, as well as an existing collaboration with Allergan .

3) Burning cash was less than estimate in the second quarter, Acadia currently has over $58M in cash on hand, with a market value of only $48M.

4) The market is assigning no value to pimavanserin, and therein lies an opportunity. The phase II data was strong, and the fact that several patients have remained in the open-label program now for over four years is highly encouraging.

5) The main reason of failure in the first phase III was due to use of low dosage of 10mg. Since 40mg dosage was successful in phase II , Acadia eventually will initiate another phase 3 with 40mg.

6) Future upside to Acadia can come from the successful development of pimavanserin in second phase 3 or other neurological indications such as schizophrenia.

7) Besides the $30 million upfront payment, Acadia can earn $160 million in potential development and regulatory milestones for successful SECOND phase III , another $45 million in potential development and regulatory milestones for additional indications such as schizophrenia, and $160 million in potential sales related milestones.

8) Biovail is an excellent commercial partner for Acadia. As you recall few days after the Acadia/Biovail transaction, Biovail acquired the U.S. Wellbutrin XL rights from Glaxo (GSK), so the company is clearly making a strong push into the CNS market.

9) Acadia did run a phase II study of Pimavan and presented results in April 2008 at a neurology conference. Acadia successfully demonstrated that treatment with pimavan was associated with four-point decrease in psychosis compared to placebo, as measured by the Scale for the Assessment of Positive Symptoms.

10) Acadia shares are SLOWLY accumulated by institutional due to its undervaluation.

Tommy,

I think ACAD is a good company with great potential, but I really think you guys are gonna get burned on the FDA's decision on this one. I'm not giving advice or telling people not to buy- rather a tip of caution.